Table 3

Univariate Cox regression analyses of systemic-recurrence-free survival and breast-cancer specific survival
BM samples Parameter Hazard ratio 95% CI P-values
Systemic recurrence-free survival
BM1 DTC status (pos. vs. neg.) 5.944 2.713–13.022 <0.001
BM2* DTC status (pos. vs. neg.) 5.013 2.133–11.782 <0.001
BM3* DTC status (pos. vs. neg.) 3.680 1.062–12.744 0.040
BM2 and/or BM3 DTC status (pos. vs. neg.) 4.523 2.044–10.008 <0.001
BM1 and BM2/3 DTC status (pos. vs. neg.) 9.948 4.103–24.122 <0.001
Lymph node status (pN > 0 vs. pN0) 3.995 1.833–8.708 <0.001
Tumor size (pT3 and pT4 vs. pT2 vs. pT1) 1.523 0.691–3.358 0.297
Tumor grade (3 vs. 2 vs. 1) 2.015 1.212–3.352 0.007
Age (>55 or not) 1.044 0.484–2.252 0.913
ER (positive vs. negative) 0.322 0.143–0.723 0.006
PgR (positive vs. negative) 0.735 0.337–1.605 0.440
Adjuvant chemotherapy (received or not) 1.603 0.713–3.601 0.253
Adjuvant endocrine therapy (received or not) 1.814 0.832–3.951 0.134
Breast-cancer specific survival
BM1 DTC status (pos. vs. neg.) 5.408 2.271–12.880 <0.001
BM2* DTC status (pos. vs. neg.) 3.880 1.470–10.238 0.006
BM3* DTC status (pos. vs. neg.) 4.626 1.286–16.635 0.019
BM2 and/or BM3 DTC status (pos. vs. neg.) 3.851 1.592–9.316 0.003
BM1 and BM2/3 DTC status (pos. vs. neg.) 9.205 3.526–24.031 <0.001
Lymph node status (pN > 0 vs. pN0) 4.694 1.944–11.344 0.001
Tumor size (pT3 and pT4 vs. pT2 vs. pT1) 1.788 0.753–4.247 0.188
Tumor grade (3 vs. 2 vs. 1) 3.288 1.743–6.201 <0.001
Age (>55 or not) 1.384 0.583–3.284 0.461
ER (positive vs. negative) 0.217 0.091–0.516 0.001
PgR (positive vs. negative) 0.729 0.306–1.733 0.474
Adjuvant chemotherapy (received or not) 1.545 0.623–3.833 0.348
Adjuvant endocrine therapy (received or not) 1.820 0.766–4.324 0.175

BM1 drawn prior to surgery, BM2 drawn three weeks after surgery, BM3 drawn six months after surgery;BM bone marrow; DTC disseminated tumor cell; ER Estrogen receptor; PgR Progesterone receptor; BM2/3 BM2 and/or BM3.

*only patients with this sample available were included in the analysis.

Tjensvoll et al.

Tjensvoll et al. BMC Cancer 2012 12:190   doi:10.1186/1471-2407-12-190

Open Data